Reference — Pulmonary Diseases
COPD Pharmacologic Management
The drugs that control COPD — maintenance bronchodilators and inhaled corticosteroids by class, the GOLD group that decides where to start, and the pharmacology of an acute exacerbation — with the bedside notes that change RT practice.
Written by Apex Respiratory Editorial Team
Educational use only. This material supports respiratory therapy education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional protocols, or physician orders. Always follow facility policies and current provider orders, and verify calculations independently before clinical use.
Overview
COPD pharmacotherapy has two goals: relieve symptoms and reduce the risk of future exacerbations. No inhaled drug reverses the underlying airflow limitation, so therapy is built on long-acting bronchodilators, with an inhaled corticosteroid added selectively when the eosinophil count and exacerbation history justify it. The GOLD assessment — symptom burden plus exacerbation risk — decides the starting regimen, and therapy is then stepped up or switched based on response.
Maintenance Therapy by Class
| Class | Examples | Role in COPD | Key RT Notes |
|---|---|---|---|
| SABA | Albuterol, levalbuterol | Short-acting rescue bronchodilation | As-needed relief of acute symptoms; onset within minutes. |
| SAMA | Ipratropium | Short-acting rescue bronchodilation | Often combined with a SABA for acute relief; dry mouth is common. |
| LABA | Salmeterol, formoterol, olodaterol | Maintenance bronchodilation | Reduces symptoms and exacerbations; a foundation of maintenance therapy. |
| LAMA | Tiotropium, umeclidinium, glycopyrrolate | Maintenance bronchodilation — strongest exacerbation reduction | Mainstay of COPD maintenance; once- or twice-daily dosing. |
| LABA + LAMA | Umeclidinium/vilanterol, tiotropium/olodaterol | Dual long-acting bronchodilation | Preferred maintenance for most symptomatic COPD; single inhaler. |
| ICS (in combination only) | Budesonide, fluticasone | Anti-inflammatory add-on to reduce exacerbations | Eosinophil-guided (favored at blood eos ≥300); never monotherapy in COPD; raises pneumonia risk. |
| Triple therapy (LABA + LAMA + ICS) | Fluticasone/umeclidinium/vilanterol, budesonide/glycopyrrolate/formoterol | Maximal inhaled therapy | For continued exacerbations on dual bronchodilation, eosinophil-guided. |
| PDE4 inhibitor | Roflumilast | Oral anti-inflammatory | Chronic-bronchitis phenotype with severe airflow limitation and exacerbations; GI upset, weight loss. |
| Chronic macrolide | Azithromycin | Anti-inflammatory / antimicrobial | Reduces exacerbations in selected patients; check QTc, hearing, and resistance risk. |
Theophylline (a weak methylxanthine bronchodilator) is now rarely used given its narrow therapeutic window and the need for serum-level monitoring.
Initial Therapy by GOLD Group
| Group | Definition | Recommended Initial Therapy |
|---|---|---|
| Group A | 0–1 moderate exacerbations (no hospitalization); low symptom burden (mMRC 0–1 / CAT <10) | A bronchodilator (short- or long-acting) |
| Group B | 0–1 moderate exacerbations; higher symptom burden (mMRC ≥2 / CAT ≥10) | LABA + LAMA |
| Group E | ≥2 moderate exacerbations or ≥1 leading to hospitalization | LABA + LAMA; add ICS if blood eosinophils ≥300 cells/µL |
GOLD now sorts patients into groups A, B, and E (the former groups C and D were merged into E in the 2023 revision). The spirometric grade (GOLD 1–4) describes airflow severity separately and does not by itself set the drug regimen.
Acute Exacerbation Pharmacology
| Intervention | Detail |
|---|---|
| Short-acting bronchodilators | Increase the dose and frequency of a SABA, with or without a SAMA; deliver by nebulizer or MDI with spacer. |
| Systemic corticosteroids | Prednisone 40 mg daily for 5 days (or equivalent) shortens recovery time and improves FEV₁ and oxygenation. |
| Antibiotics | Indicated with increased sputum purulence plus increased volume or dyspnea, or if mechanically ventilated; typically a 5–7 day course. |
| Controlled oxygen | Titrate to SpO₂ 88–92% to avoid worsening hypercapnia; a Venturi mask delivers a precise FiO₂. |
| Noninvasive ventilation | First-line for hypercapnic respiratory acidosis (pH ≤7.35 with PaCO₂ >45 mm Hg); reduces intubation and mortality. |
Clinical Notes
- ICS is eosinophil-guided, never monotherapy. In COPD an inhaled corticosteroid is added to bronchodilators to cut exacerbations — favored when blood eosinophils are ≥300 cells/µL — and it is weighed against a real increase in pneumonia risk.
- Target SpO₂ 88–92% in an exacerbation. Over-oxygenation can blunt respiratory drive and worsen hypercapnia. Controlled oxygen by Venturi mask, titrated to that window, is safer than a high-flow non-rebreather.
- LAMA gives the strongest exacerbation reduction. When a single long-acting bronchodilator is chosen, the antimuscarinic class has the best exacerbation data.
- Reversibility is not required to treat. COPD bronchodilators improve symptoms, hyperinflation, and exercise tolerance even when spirometry shows little acute FEV₁ change.
- Confirm technique and adherence before escalating. Poor inhaler technique mimics drug failure. Re-teach the device and verify adherence before stepping a regimen up.
Related Resources
Sources
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease (current annual report). GOLD.
- Kacmarek RM, Stoller JK, Heuer AJ. Egan's Fundamentals of Respiratory Care. 12th ed. Elsevier; 2021. Chronic obstructive pulmonary disease and pharmacology chapters.
- Gardenhire DS. Rau's Respiratory Care Pharmacology. 10th ed. Elsevier; 2019.